Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CABA
CABA logo

CABA News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CABA News

Cellares Successfully Infuses CAR T Therapy into Cabaletta Bio Patients

5d agoseekingalpha

Cellares and Cabaletta Bio Successfully Infuse First Patients with Rese-cel

5d agoNewsfilter

Cabaletta Bio Reports Q4 Earnings Beat with Cash Position Update

Mar 23 2026seekingalpha

Cabaletta Bio (CABA) Shares Surge 11% Following Insider Purchases

Jan 22 2026seekingalpha

High Roller Technologies Inc Closes Direct Offering, Raises $25 Million

Jan 22 2026Benzinga

IO Biotech (IOBT) Explores Strategic Alternatives, Stock Surges 19.36%

Jan 22 2026NASDAQ.COM

Cabaletta Bio (CABA) Shares Rise Nearly 6% on Clinical Progress

Jan 20 2026NASDAQ.COM

FDA's Strict Stance Creates Uncertainty for uniQure's Fast-Tracked Huntington's Gene Therapy

Nov 04 2025Benzinga

CABA Events

04/14 16:40
Cellares and Cabaletta Bio Infuse CAR T Cell Therapy for First Patients
Cellares announced that Cabaletta Bio Inc.'s investigational CAR T cell therapy rese-cel has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle automated manufacturing platform. The administration of an autologous cell therapy, which met all release criteria and was manufactured on an automated manufacturing platform, represents an important step on the journey to realizing a future where scalable manufacturing of autologous products to supply thousands of patients per year can be achieved with minimal capital investment and a low cost of goods. "This is an important milestone that reflects focused collaboration between the teams at Cabaletta and Cellares since 2023," said Steven Nichtberger, M.D., Co-founder, Chairman, and Chief Executive Officer of Cabaletta Bio. "The dosing of these first two patients is an important demonstration of Cellares' GMP manufacturing and supply chain capabilities with their automated manufacturing platform and thus represents a significant achievement towards our goal of securing high-capacity flexible supply with minimal capital investment and a low cost of goods."
03/23 16:40
Trump Claims US-Iran Talks Boost Markets
The major averages closed sharply higher after President Donald Trump said the U.S. and Iran have held talks and that he was ceasing plans to attack Iranian power plants and energy infrastructure. Of note, however, AP reported that two Iranian semi-official news agencies close to the paramilitary Revolutionary Guard claim that there have been no such negotiations. Following Trump's comments, oil prices sharply pulled back, while shares of airlines and cruise lines advanced.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Elon Musk plans to start his Terafab project, which will be run by Teslaand SpaceX, in Austin, Texas,U.S. Senators have introduced a bill aiming to ban sports bets on prediction markets,Activist investor Elliot Management has built a stake in Synopsys,Palantir'sMaven AI system will be adopted by the Pentagon as a core military system,Delta Air Linessaid thatat New York's LaGuardia Airport following the collision of an Air Canadaplane into a Port Authority firetruck that resulted in two pilot deaths2. WALL STREET CALLS:MongoDBto Outperform from Neutral at MizuhoRaymond JamesAeroVironmentafter share underperformanceValvolineto Buy at StifelMacquarieXPengwith 2026 volume growth "no guarantee"William Blaira handful of names in infrastructure software, including Backblaze, N-able, GitLaband Dropboxto Underperform3. AROUND THE WEB:Gileadis near a deal to buy Ouro Medicines for up to $2B, FT reportsOpenAI offers buyout firms sweeter deals than Anthropic, Reuters reportsSonyis close to a deal to sell a majority stake in its home entertainment business to Chinese rival TCL Electronicsin a deal that may be valued at about $1B, Bloomberg reportsUnited Airlinesplans to cut additional unprofitable flights over the next two quarters as it braces for sustained high jet fuel prices tied to the Iran war, despite strong travel demand and higher fares, Reuters saysMP MaterialsCEO James Litinsky has repositioned the company as a key U.S. rare earths supplier amid rising geopolitical tensions and Chinese export restrictions, CBS News reports4. MOVERS:Apogee Therapeuticsgained afterfrom Phase A of its Phase 2 APEX trial of zumilokibartTeraWulfadvanced after Areteof the stock with a Buy ratingEstee Lauder (EL) dropped after Puig Brandsconfirmed that it is in discussions regarding a potential business combination with the companyEquinordeclined after230MW Esquina do Vento onshore wind complex from VestasPG&Efell after Jefferiesthe stock to Hold5. EARNINGS/GUIDANCE:Talphera, with EPS higher year-over-yearOndasreportedand provided guidance for FY26 and Q1Solo BrandsprovidedCabaletta Bio, with EPS beating consensusChina Petroleum and Chemicalreported, with EPS and revenue lower year-over-yearINDEXES:The Dow rose 631.00, or 1.38%, to 46,208.47, the Nasdaq gained 299.15, or 1.38%, to 21,946.76, and the S&P 500 advanced 74.52, or 1.15%, to 6,581.00.

CABA Monitor News

Cabaletta Bio Shares Surge on Insider Purchases and Clinical Progress

Jan 22 2026

CABA Earnings Analysis

No Data

No Data

People Also Watch